Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (53)

2024

  1. 2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?

    Contact Dermatitis, Vol. 90, Núm. 5, pp. 507-513

  2. Allergic contact dermatitis in adults with and without atopic dermatitis: Evaluation of the Spanish Contact Dermatitis Registry (REIDAC)

    Contact Dermatitis

  3. Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC)

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 6, pp. 539-546

  4. Four-year Epidemiological Surveillance of the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy: Current Situation and Trends

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 4, pp. 331-340

  5. Melanoma Registry of the Spanish Academy of Dermatology and Venereology (REGESMEL): Description and Data in its First Year of Operation

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 663-669

  6. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

  7. Sensitization to textile dyes in Spain: Epidemiological situation (2019–2022)

    Contact Dermatitis, Vol. 90, Núm. 5, pp. 486-494

  8. Sodium metabisulfite a current low relevant allergen in Spain

    Journal of the European Academy of Dermatology and Venereology

  9. Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects

    Actas Dermo-Sifiliograficas

  10. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain

    Journal of the European Academy of Dermatology and Venereology

  2. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

    Actas Dermo-Sifiliograficas

  3. Erythrodermic Psoriasis Has Become Less Frequent: Results From the Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T366-T369

  4. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 291-298

  5. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas

  6. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation

    Contact Dermatitis, Vol. 88, Núm. 3, pp. 212-219

  7. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T479-T487

2022

  1. Differences in epidemiology, comorbidities and treatment choice between plaque psoriasis and pustular psoriasis: results from the BIOBADADERM registry

    British Journal of Dermatology

  2. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

  3. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406